The Disruptive Power of Weight Loss Drugs Is Being Felt Beyond Pharma

The rise of diabetes and weight loss drugs like Ozempic is not only impacting pharmaceutical companies, but also retailers, makers of weight loss products, and other industries, with knock-on effects ranging from increased foot traffic in stores and changing consumer behavior to potential disruptions in the diet industry.

nytimes.com

Relevant topic timeline:

9/5/2023

Weight-Loss Drug Stocks Are Soaring. Why There’s More Room to Run.

Weight-loss drugs are becoming increasingly popular and are expected to have a significant impact on the pharmaceutical industry.

9/13/2023

Danish Economy Avoids Recession Thanks to Novo Nordisk's Anti-Obesity Drugs

The sale of anti-obesity drugs in Denmark, particularly Ozempic and Wegovy, has significantly boosted the country's economy and prevented it from entering a recession, with the pharmaceutical industry adding almost two percentage points of growth to the GDP in the first half of 2023. The success of these drugs has also made Novo Nordisk, the company behind them, the highest valued company in Europe.

9/20/2023

New Obesity Drugs Could Transform Health but Disrupt Major Industries

Anti-obesity drugs developed by Novo Nordisk and Eli Lilly have the potential to transform public health but could also disrupt industries such as food, fitness, and healthcare, affecting companies like Nestlé and McDonald's.

9/21/2023

New Obesity Drugs Promise Weight Loss But Could Overwhelm Health System

The introduction of weight-loss drugs like Wegovy could lead to a healthcare crisis, as the cost and demand for these medications may overwhelm insurers, employers, and government programs that purchase medications in the United States.